Statistical controversies in clinical research: should schedules of tumor size assessments be changed?

about

Optimizing drug development in oncology by clinical trial simulation: Why and how?

P2860

Q38675644-3E8A3398-FA18-4A83-8BD0-9CF4C6125D79

P2860

Statistical controversies in clinical research: should schedules of tumor size assessments be changed?

Item

http://www.wikidata.org/entity/Q38922196

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Statistical controversies in c ...... r size assessments be changed?

@en

type

Item

label

Statistical controversies in c ...... r size assessments be changed?

@en

prefLabel

Statistical controversies in c ...... r size assessments be changed?

@en

P1476

Statistical controversies in c ...... r size assessments be changed?

@en

P2093

A Duhamel

http://www.w3.org/2001/XMLSchema#string

A Kramar

http://www.w3.org/2001/XMLSchema#string

E Tresch-Bruneel

http://www.w3.org/2001/XMLSchema#string

J Gilhodes

http://www.w3.org/2001/XMLSchema#string

N Houédé

http://www.w3.org/2001/XMLSchema#string

W Kouokam

http://www.w3.org/2001/XMLSchema#string

P2860

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Joint modeling tumor burden and time to event data in oncology trials.

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Recommendations for the assessment of progression in randomised cancer treatment trials.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

The power of phase II end-points for different possible mechanisms of action of an experimental treatment

Tumour growth kinetics assessment: added value to RECIST in cancer patients treated with molecularly targeted agents

Improving the design of phase II trials of cytostatic anticancer agents.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

Alternate endpoints for screening phase II studies.

P304

1981-1987

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDW292

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Filleron

Nicolas Penel

Florence Joly

P577

2016-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27502711

http://www.w3.org/2001/XMLSchema#string

Statistical controversies in clinical research: should schedules of tumor size assessments be changed?

about

P2860

P2860

Statistical controversies in clinical research: should schedules of tumor size assessments be changed?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698